Table 2.
Summary of biomarkers and their efficacy.
| Treatment | Patients number | Subpopulation | Outcome | Marker | Result (95% Cl) RR = 14% | p-value | References |
|---|---|---|---|---|---|---|---|
| Nivolumab | n = 90 | LDH (upper normal limit) | RR | NLR > 2.2 NLR < 2.2 |
RR = 14% RR = 57% |
<0.05 | (14) |
| LDH normal | RR | NLR > 2.2 NLR < 2.2 |
RR = 37% RR = 67% |
<0.001 | |||
| Nivolumab | n = 87 | OS | Monocyte count (upper normal limit) | HR = 4.31 (1.46–12.74) | 0.01 | (15) | |
| PFS | Monocyte count (upper normal limit) | HR = 3.5 (1.01–12.1) | 0.04 | ||||
| Nivolumab + lpllimumab | n = 209 | OS | NLR Eosinophils Basophils Absolute monocyte LDH (246 <) |
HR = 1.95 (111–3.47) HR = 2.38 (1.27–4.46) HR = 1.86 (0.94–3.66) HR = 2.75 (1.30–5.80) HR = 3.71(2.08–6.61) |
0.02 0.007 0.08 0.01 <0.0001 |
(16) | |
| Lpllimumab | n = 183 | OS | Baseline NLR NLR (end of treatement) |
HR = 1.06 (1.01–1.10) HR = 1.06 (1.02–1.09) |
0.016 <0.001 |
(17) | |
| Lpllimumab | n = 720 | OS PFS |
ANC ANC |
HR = 3.38 (2.62–4.36) HR = 2.52 (1.97–3.21) |
<0.0001 <0.0001 |
(18) | |
| Anti-PD1 antibody | n = 66 | OS | LDH elevated LDH normal |
4.3 months 15,7 months |
<0.00623 | (22) | |
| Nivolumab | n = 210 | RR | PD-L1 positive PD-L1 negative |
52.7% (40.8–64.3) 33.1% (25.2–41.7) |
(23) | ||
| Nivolumab | n = 59 | RR | Increased Scd163 | Sensitivity 84.6% Specificity 87.0% | <0.0030 | (24) |
ANC, absolute neutrophilcount; HR, hazzard ratio; NLR, neutrophilto lymphocyte ratio; OS, overall survival; PFS, progress free survival; RR, response rate; UNL, under normal limit.